The most successful patients use the medication as a tool to reset their relationship with food, build sustainable habits during treatment, and work with their provider on a long-term plan
10.1016/j.jnutbio.2012.11.003 447
These drugs may still be appropriate, however, in certain situations, such as for high-risk patients (e.g., those contraindicated for surgery)
Studies show that people taking GLP-1-based therapy (including exenatide, liraglutide, dulaglutide, semaglutide, or tirzepatide) are four times more likely to have food stuck in their stomachs during endoscopy (13.6% versus 2.3% in non-users) [6]
Under CEO Jrgensen, Novo hired media giant Wavemaker, whose clients include LOral and Tiffany